Evofem Biosciences competitors

• Pharmaceutical/Biotech executive with over 23 years’ experience in successful commercialization (sales, marketing, trade, managed markets, training and development, market research, sales operations, supply chain), general operations (IT, facilities), business development, leadership development, investor relations and strategic planning. • Proven track record of commercialization success in diverse business structures including large public pharma, start-up specialty private pharma and public biotech inclusive of building and scaling commercial operations to the needs of the organization. • Accomplishments include launching a blockbuster mass market brand/category, re-launching specialty and mass market brands to generate positive brand P&Ls, and corporate M&A leading to the exit of a specialty pharma company for $1.65B.

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

President and Chief Executive Officer Jim Clemmer joined AngioDynamics in April 2016, bringing more than 25 years of leadership within the healthcare industry and a proven track record of success. Prior to AngioDynamics, Clemmer served as president of the $1.8 billion medical supplies segment at Covidien plc., where he directed strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Clemmer served as group president at Kendall Healthcare, where he managed the US business across five divisions and built the strategic plan for the Medical Supplies segment before it was spun off from Tyco. Clemmer began his career at Sage Products, Inc. Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging. Clemmer is a graduate of the Massachusetts College of Liberal Arts.

Mr. White leads Aptevo Therapeutics as the President and Chief Executive Officer. Prior to this role he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards WP Glimcher and OneAmerica Financial Partners Inc., and was previously on the board of of CoLucid Pharmaceuticals, Inc.

Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.

Dom Meffe is a President/CEO at Triad Isotopes.